



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Co-infections: potentially lethal and unexplored in COVID-19

Respiratory viral infections predispose patients to co-infections and these lead to increased disease severity and mortality. Most fatalities in the 1918 influenza outbreak were due to subsequent bacterial infection, particularly with *Streptococcus pneumoniae*.¹ Poor outcomes in the 2009 H1N1 influenza pandemic were also associated with bacterial co-infections, although few studies captured these data.²

Despite the proven importance of co-infections in the severity of respiratory diseases, they are understudied during large outbreaks of respiratory infections. Zhou and colleagues³ showed that in the current coronavirus disease 2019 (COVID-19) pandemic, 50% of patients with COVID-19 who have died had secondary bacterial infections, and Chen and colleagues⁴ have recorded both bacterial and fungal co-infections. Although 71% of the admitted patients with COVID-19 received antibiotic drugs, no information is available on the antimicrobial sensitivities of the organisms that were identified, or on the type and duration of antimicrobial treatment. Chronic obstructive pulmonary disease (COPD) is a risk factor for severe COVID-19 disease and many patients with COPD will have underlying chronic bacterial infections before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but this important

information is not being reported. More data on co-infections are urgently required to establish their importance in COVID-19 severity and mortality.

Diagnosing co-infections is complex. The organism itself might be carried by the patient before the viral infection, might be part of an underlying chronic infection, or might be picked up nosocomially. In the UK, National Institute for Health and Care Excellence (NICE) treatment guidance for severe acquired pneumonia is broad-spectrum antibiotic co-amoxiclav plus a macrolide to cover atypical organisms. Currently, antibiotic use is high (74.5%) among patients with COVID-19 who are admitted to intensive care units, rendering culture-based microbiological testing less sensitive. Patients with COVID-19 are kept on invasive mechanical ventilation for a long time (mean 9.1 days [SD 5.5]), increasing chances of hospital and ventilator acquired infections. Hence, early diagnosis of co-infection is required, preferably using methods capable of detecting a broad range of potential pathogens and antimicrobial resistances, with subsequent monitoring for infection development. To accurately diagnose and study co-infection in COVID-19, patients should be recruited on admission to intensive care units and sampled longitudinally throughout the disease course using culture-independent techniques capable of identifying complex mixed infections without previous target selection, such as whole-genome metagenomics.⁵ Such a study would provide valuable surveillance data on

the pathogens causing co-infections and antimicrobial resistance in the intensive care setting, thereby helping inform antibiotic prescribing policy.

Rapid characterisation of co-infection is essential in the management and treatment of the most severe COVID-19 cases, could help to save lives, and will improve antimicrobial stewardship throughout the course of the pandemic.

DB has received research grants from MedImmune, outside of the submitted work. All other authors declare no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

**Michael J Cox, Nicholas Loman, Debby Bogaert, Justin O'Grady*
m.j.cox@bham.ac.uk

Institute of Microbiology and Infection, University of Birmingham, Birmingham B15 2TT, UK (MJC, NL); Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK (DB); Quadram Institute Bioscience, Norwich, UK (JO); and Norwich Medical School, University of East Anglia, Norwich, UK (JO)

- 1 Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. *J Infect Dis* 2008; **198**: 962–70.
- 2 MacIntyre CR, Chughtai AA, Barnes M, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. *BMC Infect Dis* 2018; **18**: 637.
- 3 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054–62.
- 4 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507–13.
- 5 Charalampous T, Kay GL, Richardson H, et al. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection. *Nat Biotechnol* 2019; **37**: 783–92.



Published Online
April 24, 2020
[https://doi.org/10.1016/S2666-5247\(20\)30009-4](https://doi.org/10.1016/S2666-5247(20)30009-4)

For further discussion about co-infection and COVID-19 see <https://www.covid-coinfections.org>

For data from the International Severe Acute Respiratory and Emerging Infection Consortium see <http://ISARIC.tghn.org>